sinecatechins 10% topical ointment — Competitive Intelligence Brief

sinecatechins 10% topical ointment (sinecatechins 10% topical ointment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral. Area: Dermatology.

phase 3 Antiviral Human papillomavirus (HPV) E6 and E7 proteins Dermatology Small molecule

Target snapshot

sinecatechins 10% topical ointment (sinecatechins 10% topical ointment) — Hospital Universitari Vall d'Hebron Research Institute. Sinecatechins 10% topical ointment works by inhibiting the replication of human papillomavirus (HPV) in the skin.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sinecatechins 10% topical ointment TARGET	sinecatechins 10% topical ointment	Hospital Universitari Vall d'Hebron Research Institute	phase 3	Antiviral	Human papillomavirus (HPV) E6 and E7 proteins
Paxlovid (Copackaged)	Nirmatrelvir	Pfizer	marketed	Antiviral protease inhibitor	SARS-CoV-2 main protease (Mpro, 3CLpro, nsp5 protease)	2023-01-01
Lonsurf	TIPIRACIL	Taiho Oncology Inc	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	2015-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
Dendrid	IDOXURIDINE	Novartis	marketed	Nucleoside Analog Antiviral	Thymidine kinase, cytosolic	1963-01-01
sofosbubir/velpatasvir	sofosbubir/velpatasvir	Partners in Health	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase and NS5A protein
Peg-IFN + WB RBV for 24 weeks	Peg-IFN + WB RBV for 24 weeks	National Taiwan University Hospital	marketed	Immunomodulator + nucleoside analog antiviral combination	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-09-22 — Lonsurf · RE46284 · US
• 2034-06-17 — Lonsurf · 10457666 · US
• 2034-06-17 — Lonsurf · 9527833 · US
• 2034-09-05 — Lonsurf · 9943537 · US
• 2037-02-03 — Lonsurf · 10456399 · US
• 2037-02-03 — Lonsurf · 10960004 · US
• 2041-08-05 — Paxlovid (Copackaged) · 11351149 · US
• 2041-10-31 — Paxlovid (Copackaged) · 11541034 · US

Sponsor landscape (Antiviral class)

1. Ain Shams University · 1 drug in this class
2. Arbutus Biopharma Corporation · 1 drug in this class
3. Australasian Gastro-Intestinal Trials Group · 1 drug in this class
4. Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
5. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
6. Invivyd, Inc. · 1 drug in this class
7. JW Pharmaceutical · 1 drug in this class
8. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
9. Pfizer · 1 drug in this class
10. Professor Francois Venter · 1 drug in this class